Claudin 18.2 antibodies, antigen binding fragments and antibody drug conjugates thereof and methods of use in cancer therapy

Anti-CLDN18.2 antibodies and ADCs with specific CDR sequences address the limitations of existing therapies by enhancing binding affinity and efficacy, effectively targeting and killing CLDN18.2-positive cancer cells, particularly in gastric, pancreatic, and lung tumors.

WO2026115454A2PCT designated stage Publication Date: 2026-06-04ASTRAZENECA AB
View PDF 7 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
ASTRAZENECA AB
Filing Date
2025-11-26
Publication Date
2026-06-04

Smart Images

  • Figure IB2025062094_04062026_PF_FP_ABST
    Figure IB2025062094_04062026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are antibodies, antigen binding fragments, and immunoconjugates thereof that specifically bind to claudin 18.2 expressing cells, along with pharmaceutical compositions and kits comprising the antibodies, antigen binding fragments, and / or immunoconjugates. Methods of use of the antibodies, antigen binding fragments, and immunoconjugates in the treatment of claudin 18.2 expressing tumor cells is also provided.
Need to check novelty before this filing date? Find Prior Art